Health Canada

Merit Medical Systems has enrolled the first patient in its WRAP North America registry, a prospective multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY Cell-Impermeable Endoprosthesis for hemodialysis patients.

Health Canada granted conditional marketing authorization for AMTAGVI, marking the first T-cell therapy approved for solid tumors in Canada, specifically for advanced melanoma treatment.

Health Canada approved Ozempic on August 13 to reduce kidney deterioration risk in Type 2 diabetes patients with chronic kidney disease.

Amansa Investments has completed a ₹250 crore pre-IPO investment in pharmaceutical formulations company Rubicon Research, acquiring shares at ₹484.47 per share.

Iovance Biotherapeutics reduced its workforce by 19% in Q3 2025 and targets $100 million in annual savings to extend cash runway to late 2026.

Iovance Biotherapeutics achieved $60.0 million in total product revenue for Q2 2025, representing a 93% year-over-year increase driven by strong Amtagvi adoption.

Health Canada has approved Dyanavel XR, an extended-release amphetamine formulation available as both tablets and oral suspension, for treating ADHD in adults 18 years and older and children aged 6-12 years.

Rapid Dose Therapeutics has submitted a product application to Health Canada for approval of its QuickStrip Nicotine products in four dose strengths (1-4 mg), marking a significant regulatory milestone for the innovative oral nicotine delivery system.

Health Canada has granted approval for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in treating uveitic macular edema, expanding the drug's global reach.

Nanochon has received Health Canada approval for a first-in-human clinical trial of its 3D printed Chondrograft implant to treat articular cartilage defects in the knee.